The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 21, 2021

Filed:

Sep. 19, 2017
Applicants:

Universitat DE Valencia, Valencia, ES;

Aum Lifetech, Inc., Philadelphia, PA (US);

Inventors:

Rubén D. Artero Allepuz, Valencia, ES;

María Beatriz LlamusíTroisi, Valencia, ES;

Estefanía Cerro Herreros, Valencia, ES;

Juan M. Fernández Costa, Valencia, ES;

Veenu Aishwarya, Philadelphia, PA (US);

Thorleif Møller, Årslev, DK;

Assignees:

UNIVERSITAT DE VALENCIA, Valencia, ES;

AUM LIFETECH, INC., Philadelphia, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/7115 (2006.01); C12N 15/113 (2010.01); A61P 25/14 (2006.01); A61P 21/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7115 (2013.01); A61P 21/00 (2018.01); A61P 25/14 (2018.01); C12N 15/113 (2013.01); C12N 2310/113 (2013.01); C12N 2310/141 (2013.01);
Abstract

Modulation of microRNAs against myotonic dystrophy type 1 and antagonists of microRNAs therefor. The invention provides the use of inhibitors of microRNAs repressors of MBNL1 and/or MBNL2 genes for the manufacture of a medicinal product for the treatment of myotonic dystrophy 1. Inhibiting these microRNAs allows to increase the endogenous levels of the corresponding proteins MBNL1 and/or MBNL2, thereby alleviating symptoms of the disease, especially when inhibiting repressors that are expressed in the main affected organs: skeletal muscle, heart or organs of the central nervous system. The inhibition of the microRNAs miR-23b-3p and miR-218-5p is preferred. It also provides oligoribonucleotide or oligoribonucleotide analogue antagonists suitable therefor, preferably antagomiRs directed against the microRNAs mentioned with chemical modifications that enhance their interaction with the target, their stability in vivo and their ability to penetrate into the cells and distribute throughout tissues and organs.


Find Patent Forward Citations

Loading…